Core Viewpoint - Notai Bio will be subject to other risk warnings and will be suspended from trading for one day starting July 21, following the issuance of an administrative penalty notice by the China Securities Regulatory Commission (CSRC) [2][10]. Group 1: Administrative Penalty - The CSRC's administrative penalty notice indicates that Notai Bio's 2021 annual report contains false records and that the company fabricated significant false content in its public offering documents [4][8]. - Notai Bio's business transaction with Zhejiang Huabei Pharmaceutical Co., Ltd. in December 2021 led to an inflated revenue of 30 million yuan and an inflated profit of 25.9516 million yuan, accounting for 20.64% of the total profit disclosed for that period [7]. Group 2: Risk Warning Implementation - Starting July 22, Notai Bio will have its stock trading name changed to ST Notai due to the identified violations, in accordance with the Shanghai Stock Exchange's rules [10]. - During the period of other risk warnings, Notai Bio's stock will not be traded on the risk warning board, but the price fluctuation limit remains at 20% [11]. Group 3: Financial Outlook - Notai Bio projected a net profit attributable to shareholders of 300 million to 330 million yuan for the first half of 2025, representing a year-on-year growth of 32.06% to 45.27% [11].
突发！688076，将被ST！